Pancreatic cancer remains one of the hardest tumors to treat, in part because it builds a defensive shell that keeps the immune system from mounting a strong attack. Researchers at the University of Chicago have taken an unusual route around that barrier: they engineered a common probiotic bacterium to slip inside pancreatic tumors and manufacture an immune-stimulating drug right where it is needed. In animal studies, the modified bacteria accumulated in tumors, switched on cancer-fighting immune cells and slowed tumor growth, though the approach has not yet been tested in people.
Why pancreatic tumors evade the immune system
Immunotherapies have transformed treatment for several cancers, but pancreatic tumors often create what scientists call a “cold” microenvironment, one that actively blocks immune cells from infiltrating and attacking. That resistance is a major reason the disease carries such a grim prognosis. Delivering immune-activating drugs to the tumor without flooding the rest of the body has proven difficult, which is what makes a targeted delivery vehicle so appealing, according to the University of Chicago Medicine.
Turning a gut microbe into a drug factory
The engineered strain, named BifidoSumIL-2, is built from Bifidobacterium longum, a probiotic bacterium naturally found in the human gut and commonly present in yogurt. The researchers chose it in part because it is an obligate anaerobe, meaning it cannot grow in the presence of oxygen. After the bacteria are injected into the bloodstream, they are cleared from oxygen-rich healthy tissues but can take hold in the low-oxygen interior of solid tumors, including pancreatic ones. That tumor-seeking behavior lets the microbes act like microscopic factories, producing their cargo only where the disease is.
The cargo is SumIL-2, an engineered version of interleukin-2, a powerful immune molecule that activates the T cells the body uses to fight cancer. Standard IL-2 therapy can cause harmful side effects and can also switch on immune cells that suppress the antitumor response. The modified SumIL-2 is designed to stimulate cancer-fighting T cells more selectively while limiting activation of those suppressive cells, and packaging it inside the bacteria concentrates the treatment directly within the tumor.
That localization is the strategic heart of the approach. Immune-stimulating drugs are most useful when they act intensely at the tumor and minimally everywhere else, because the same molecules that rally an attack on cancer can trigger dangerous inflammation when they circulate freely through the body. By tying a potent immune signal to a microbe that only becomes active in the oxygen-starved core of a tumor, the researchers aimed to turn the tumor’s own biology, its low-oxygen interior, into the trigger that switches the therapy on. Healthy tissues, richer in oxygen, provide no foothold for the bacteria and so are largely spared.
Slowing tumor growth in animal models
In animal experiments, BifidoSumIL-2 selectively accumulated in tumors, activated immune responses and slowed pancreatic tumor growth. The treatment also reshaped the tumor environment by increasing the activity of cancer-fighting CD8+ T cells, the immune cells that directly attack malignant tissue. The work, published in the journal Science Advances, drew on expertise spanning microbiology, synthetic biology, oncology and immunology, reflecting how much cross-disciplinary effort a living therapeutic requires.
Researchers noted that Bifidobacterium is not an easy organism to engineer. It grows slowly, dies in oxygen and offers far fewer genetic tools than laboratory workhorses such as E. coli, so a substantial part of the project was simply figuring out how to modify it reliably. The bacterium’s long track record as a probiotic gave the team a favorable safety starting point in preclinical models.
Stronger when paired with standard treatments
One of the study’s most notable findings was that the therapy became more effective when combined with existing cancer treatments. Pairing BifidoSumIL-2 with chemotherapy, radiation therapy or an anti-PD-L1 immunotherapy improved tumor control and survival compared with any single treatment alone. That combination potential matters because pancreatic cancer is rarely beaten by one approach, and a tool that amplifies the drugs already in use could fit into current treatment plans.
The researchers were careful to emphasize that BifidoSumIL-2 has not been tested in humans. Future studies will need to evaluate long-term safety, possible off-target effects, how durable the immune response is and whether the bacteria could eventually be given orally rather than by injection. Introducing a living, engineered organism into a patient raises questions that a conventional drug does not, including how reliably the bacteria stay confined to the tumor and how the body clears them once treatment ends. Those are exactly the issues that regulators and clinicians would scrutinize before any human trial.
The team is also interested in combining the strategy with newer pancreatic cancer drugs, including inhibitors that target the KRAS mutations common in the disease. For now, the work adds momentum to a growing “bugs as drugs” field, in which engineered probiotic bacteria are being explored as a way to carry immune therapies straight into tumors that have long resisted attack, while sparing the rest of the body. Pancreatic cancer’s dismal survival statistics have made it a proving ground for unconventional ideas, and while a bacterial delivery system remains years from the clinic, the animal results suggest the concept is worth pursuing.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
